PUBLICATIONS & SCIENTIFIC REPORTS
Books / Monographs
K.L. Mettinger. The Ninth Day of Creation – A Brief History of the Biotech Revolution. (In Process)
K.L. Mettinger, P. Rameshwar, V. Kumar (eds): Stem Cells, microRNAs and Exosomes: Aging, Cancer and Age-Related Disorders. Nature/Springer Publishing House 2018
S. Sherry, R. Schroder, C. Kluft, A.J. Six, K.L. Mettinger. "Controversies in Coronary Thrombolysis - A Critical Assessment of Recent Developments" (Edited together with, et al, 180 pages), Current Medical Literature, London, 1989
V.V. Kakkar, J.W. Kennedy, K.L. Mettinger. "Coronary Thrombolysis - Current Answers to Critical Questions" (170 pages), Current Medical Literature, London, 1988
K.L. Mettinger. "Refaat - Myter och miljarder" ("Myths and billions. he story about Refaat El-Sayed and Fermenta," 320 pages), Timbro, Stockholm, 1987
K.L. Mettinger. Dissertation: Cerebral Thromboembolism - A Case-Control and Longitudinal Study of Blood Coagulation, Fibrinolysis and Platelet Function in Ischemic. Cerebro-vascular Disease, Department of Blood Coagulation Disorders and Neurology, Karolinska Institutet, Stockholm 1982
BOOK CHAPTERS
Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. A study of stroke before age 55. International Congress on Atherosclerosis, Milan, 1977. Ed: Carlsson LA, et al, Raven Press, New York, 227-238,1978
Blomback M, Egberg N, Frisch P, Hellgren M, Mettinger KL, Wahlberg T. Chromogenic peptide substrates in fibrinolysis. In: JF Davidson, IM Nilsson, B Astedt (Eds). Progress in Fibrinolysis V Churchill Livingstone, Edinburgh, 1981, pp 186-195
Mettinger KL. Medicine or patients? Proceedings of the Seventh International Congress of Christian
Physicians. Christian challenge to current concepts of health care, pp 40-44. Ashok Hotel, Bangalore, India, November 3-7,1982
Soderstrom CE, Mettinger KL.: Antitrombotisk behandling efter cerebral infarkt. National Board of Health and Welfare, Drug Information Committee, Sweden. Workshop “Cerebrovaskular ischemic”, 77-85, 1982:2
Mettinger KL. A study of hemostasis in ischemic cerebrovascular disease. In: A Strano (Ed). Platelet function and cardiovascular diseases. International Conference - Rome, 30-31 October 1983. Exc. Med., Amsterdam, 1984, pp 55-85
Mettinger KL. Fresh-clot selectivity - a key factor for increased safety? In: Sherry S, Schroder R, Mettinger KL et al (Eds). Controversies in Coronary Thrombolysis. A Critical Review of Recent Developments. Current Medical Literature, London, 1989
PEER REVIEWED PUBLICATIONS
Mettinger KL. Cerebrovascular complications in thrombolysis. In: VV Kakkar, JW Kennedy and KL Mettinger (Eds) Coronary Thrombolysis. Current answers to critical questions. Current Medical Literature, London 1988, pp 118-122, 1988
Kallstrand G, Siden A, Kjellin KG, Soderstrom CE, Mettinger, KL. Biofarmacevtiska faktorers inverkan pa absorptionen av dikumarol. Observanda Medica 6:166–169, 1975
Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. Aktuella synpunkter pa ischemiska cerebrovaskulara lesioner. Oversikt av utrednings- och behandlings-principer vid neurologiska kliniken, Karolinska sjukhuset. Lakartidningen 73:3973-3974, 1976
Mettinger KL, Ericson K, Larsson S, Casseborn S. Detection of atherosclerotic plaques in carotid arteries by the use of 123 I-fibrinogen. Lancet 1:242-244, 1978
Kjellin KG, Mettinger KL, Siden A, Sjostrom L, Soderstrom CE. Intracerebrala blodningar: Klinik, utredningsgang och behandlingsprinciper. Lakartidningen 75:263672639,1978
Rossner S, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. Normal serum-cholesterol but low HDL-cholesterol concentration in young patients with ischaemic cerebrovascular disease. Lancet 1:577-579, 1978
Rossner S, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. Dyslipoproteinemia in patients with ischemic cerebrovascular disease. A study of stroke before the age of 55. Atherosclerosis 30:199-209, 1978
Mettinger KL, Larsson S. Gamma scanning of atherosclerotic plaques in carotid arteries. Letter, Lancet 1:1267, 1978
Mettinger KL.Development work at a neurologic stroke unit.. Riksstamman 1977, Symposium Swedish Government Planning and Rationalization Institute (SPRI)-rapport S 95:29-30, 1978.
Mettinger KL, Soderstrom CE. Pathogenetic profile of TIA before 55. A three-year investigation. J Neurol Sci 36:341-348, 1978
Mettinger KL, et al. Detection of atherosclerotic plaques in carotid arteries by 123I-fibrinogen. Digest/Internal Medicine:21, March 1979.
Mettinger KL, Nyman D, Kjellin KG, Siden A, Soderstrom CE. Factor VIII related antigen, antithrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cardiovascular disease. A study of stroke before 55. J Neurol Sci 41:31-38, 1979
Gudmundsson G, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. Isoelectric focusing of cerebrospinal fluid proteins in ischemic cerebrovascular disease. J Neurol 222, 227-234, 1980
Mettinger KL, Blomback M. Multicenterstudier i USA och Kanada: Trombocytfunktionshammare vid ischemisk cerebrovaskular sjukdom. Lakartidningen 77:320322,1980
Blomback M, Mettinger KL, Reizenstein P. Antikoagulantiabehandling - vardkostnad och vardkvalitet. Lakartidningen 78:3891-3892, 1981
Hamberg M, Svensson J, Blomback M, Mettinger KL. Shortened megakaryocyte-platelet regeneration time in patients with ischemic cerebrovascular disease. Thromb Res 21:675-679, 1981
Soderstrom CE, Ericson K, Mettinger KL, Olivecrona H. Computed tomography and CSF spectrophotometry. Scand J Rehab Med 13:65-71, 1981
Alvan G, Beermann B, Bergentz SE, Britton M, Eckernas SA, Granstrom E, Hedner U, Ljunggren H, Lundh B, Melander A, Mettinger KL, Nilsson B, Rosen A, Thoren L, Westerberg CE, Aberg H. Sekundar profylax efter cerebrovaskulara ischemiska skador. Recommendations from Drug Information Committee, National Board of Health & Welfare, Sweden, 1982:3
Mettinger KL. A study of hemostasis in ischemic cerebrovascular disease. I. Abnormalities in factor VIII and antithrombin. Thromb Res 26:183-192, 1982
Mettinger KL, Egberg N. A study of hemostasis in ischemic cerebrovascular disease. II. Abnormalities in platelet and release, platelet cyclooxygenase regeneration time and platelet factor 3 availability. Thromb Res 26:193-201, 1982
Mettinger KL, Egberg N. A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and a2-antiplasmin. Thromb Res 26:203-210, 1982
Mettinger KL. A study of hemostasis in ischemic cerebrovascular disease. IV. A five year follow-up of some blood coagulation parameters also including fibrinopeptide A, factor XII and prekallikrein. Thromb Res 27:155-160,1982
Mettinger KL. A study of hemostasis in ischemic cerebrovascular disease. V. A multivariate evaluation of risk indicators and predictors. Early results of a longitudinal study. Thromb Res 28:521-532, 1982
Mettinger KL, Ericson K. Fibromuscular dysplasia and the brain. I. Observations on angiographic, clinical and genetic characteristics. Stroke 13:46-52, 1982
Mettinger KL. Fibromuscular dysplasia and the brain. II. Current Concepts of the Disease. Stroke 13:53-58, 1982
Svensson J, Mettinger KL, Blomback M. Letter to the editors-in-chief. Enteric-coated aspirin and cyclooxygenase inhibition. Thromb Res 29:99-102, 1983
Smith E, Hammarstrom L, Kjellin K, Mettinger KL, Siden A, Soderstrom CE. HLA and ischemic cerebrovascular disease. A study of patients with stroke before the age of 56 Acta Neurologica 38:268-271, 1983
Mettinger KL, Soderstrom CE, Neiman J. Stroke before 55 years of age at Karolinska Hospital 1973-1977. A study of 399 well defined cases. Acta Neurol Scand 70:415-422, 1984
Mettinger KL, Soderstrom CE, Allander E. Epidemiology of acute cerebrovascular disease before the age of 55 in the Stockholm county 1973-77: I. Incidence and mortality rates. Stroke 15:795-801, 1984
Mettinger KL. Responsibility and accountability. In the service of medicine, 32:1, No. 125:1621,1986
Mettinger KL. Trombolytisk behandling vid akut hjartinfarkt. Journalen, 6; 9:258-261, 1986
Mettinger KL. KabiVitrum and the cardiovascular research. In: 40 years with cardiovascular drugs. Hjart- och lungfonden. Swedish heart-lung foundation. Kvartalsskrift, Supplement 1:3637,1987
Mettinger KL. Kabikinas vid akut hjartinfarkt - ett genombrott. Journalen, 8:2:26-27, 1988
Mettinger KL Thrombolytic intervention and its effect on mortality in acute myocardium infarction. Heart Lung. Mar;19(2):213-5, 1990.
Clark WM, Coull BM, Hendin R, Kelly R, Mettinger KL, et al. Randomized trial of Cervene, a kappa receptor selective opoid antagonist in acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, Vol. 6, No. 1, pp 35-40, 1996.
Riekkinen P Jr, Mettinger KL, Karukin M, Riekkinen M. Effects of Alzene and tacrine on water maze reference and working memory function in medial septal-lesioned rats.Brain Res. 714(1-2):118-24, 1996.
Sredni B, Xu R-H, Albeck M, Gafter U, Gal R, Shani A, Tichler T, Shapira J, Bruderman I, Catane R, Kaufman B, Whisnant JK, Mettinger KL, Kalechman Y. The Protective Role of the Immunomodulator AS 101 Against Chemotherapy-Induced Alopecia Studies on Human and Animal Models. Int. J. Cancer, 65, 97-103, 1996.
Kalechman Y, Shani A, Dovrat S, Whisnant JK, Mettinger KL, Albeck M, Sredm B. The Antitumoral Effect of the Immunomodulator AS 101 and Paclitaxel (Taxol) in a Murine Model of Lung Adenocarcinoma. Journal of Immunology, 156: 1101-1109, 1996
Mettinger K. Methods on composition for treatment of ovarian cancer. World Intellectual property organization, International application published under the patent cooperation treaty (PCT), 1 October 1998
Tulpule A, Groopman J, Saville MW, Harrington W, Mettinger KL, Gill P. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS related Kaposi’s Sarcoma. Cancer 95: 147-154, 2002
de Jonge MJ, Droz JP, Paz-Ares L, van Oosterom AT, de Wit R, Chollet P, Baron B, Lacombe D, Mettinger K, Fumoleau P; EORTC-New Drug Development Group/New Drug Development Program : Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors. Invest New Drugs. 2004 Aug;22(3):329-33.
Burris HA 3rd, Rivkin S, Reynolds R, Harris J, Wax A, Gerstein H, Mettinger KL, Staddon A. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist. Mar;10(3):183-9, 2005
Baka S, Ranson M, Lorigan P, Danson S, Linton K, Hoogendam I, Mettinger K, Thatcher N. A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2005 Jul;41(11):1547-50.
Chedid S, Rivera E, Frye DK, Ibrahim N, Esteva F, Valero V, Hortobagyi G, Mettinger KL, Cristofanilli M. Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006 Apr;57(4):540-4.
Burris HA 3rd, Rivkin S, Reynolds R, Harris J, Wax A, Gerstein H, Mettinger KL, Staddon A. Phase III trial of oral rubitecan in previously treated pancreatic cancer patients. Submitted.
Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S, Goel S. Intravenous administration of REOLYSIN®, a live replication competent RNA virus is safe in patients with advanced solid tumors.Invest New Drugs. 2009 Jul 2. [Epub ahead of print]
Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, Coffey M, Mettinger K, Gill G , Evans TRJ, and de Bono J, A phase-I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res. 2011 Feb 1;17(3):581-8. Epub 2010 Nov 24.
Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White C, Vile R, Melcher A, Coffey M, Mettinger K, Nuovo G, Cohn D, Phelps M, Harrington K, S Pandha HS, REO-10: A Phase 1 Study of intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. . Clin Cancer Res. 2010 Nov 15;16(22):5564-72. Epub 2010 Oct 6.
Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ. Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clin Cancer Res. 2012 Apr 1;18(7):2080-9.
PEER REVIEWED SCIENTIFIC REPORTS / ABSTRACTS
Mettinger KL, Kjellin KG, Siden A, Soderstrom CE. Medical Therapy in ischemic cerebrovascular disease with regard to bioavailability of coumarin derivatives. VII Neurological Congress with International Participation, Bratisalava, 1976, Lect. Excc 48, 1976
Mettinger KL, Soderstrom CE Transitoriska ischemiska attacker (TIA) fore 55 ars alder. En studie av ett tre-ars material. Riksstamman 1976. Hygiea 85 (5):325, 1976.
Kallstrand G, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. Coumarin derivatives in ischemic cerebro-vascular disease (ICD). A pharmacological comparison. 11th World Congress of Neurology, Amsterdam, 1977. Exc. Med. 427:24, 1977
Nyman D, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. Circulating platelet aggregates, fibrinolytic response and factor VIII related antigen (VIII RA) in ischemic cerebro-vascular disease (ICD). A study of stroke before 55. 11th World Congress of Neurology, Amsterdam, 1977. Exc. Med. 427:3, 1977
Ericson K, Mettinger KL. Fibromuscular dysplasia (FMD). A neglected risk factor for stroke before 55? 1lth World Congress of Neurology, Amsterdam, 1977. Exc. Med. 427:48, 1977
Neiman J, Mettinger KL, Soderstrom CE. Stroke in females before 55. A study of 103 patients. 11th World Congress of Neurology, Amsterdam, 1977. Exc. Med. 427:50, 1977
Rossner S, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. Dyslipoproteinemia in ischemic cerebrovascular disease (ICD). A study of stroke before 55. 11th World Congress of Neurology, Amsterdam, 1977. Exc. Med. 427:50,1977
Mettinger KL, Ericson K, Larsson S. A model for non-invasive screening of ulcerous plaques in the carotid arteries using isotope labelled blood elements. 11th World Congress of Neurology, Amsterdam, 1977. Exc. Med. 427:48, 1977
Sjostrom L, Mettinger KL, Soderstrom CE. Intracerebral haemorrhage. A study of risk-profile, diagnosis and prognosis in a well-defined material. 11th World Congress of Neurology, Amsterdam, 1977. Exc. Med. 427:51, 1977
Soderstrom CE, Kjellin KG, Mettinger KL. A longitudinal study of computer tomography (CT) and spectrophotometry of CSF (CSF-SPE) in 350 patients with cerebrovascular disease (CVD). 11th World Congress of Neurology, Amsterdam, 1977. Exc. Med. 427:151, 1977
Gudmundsson G, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. CSF-protein abnormalities found by isoelectric focusing (IEF) in ischaemic cerebrovascular diseases (ICD). 11th World Congress of Neurology, Amsterdam, 1977. Exc. Med. 427:136, 1977
Gudmundsson G, Kjellin KG, Mettinger KL, Siden A, Sjostrom L, Soderstrom CE. Abnormal CSF-protein findings in ischaemic cerebrovascular diseases (ICD). Acta Neurol Scand (Suppl 67) 57:250, 1978
Kjellin KG, Mettinger KL, Rossner S, Siden A, Soderstrom CE. Serum-lipoprotein abnormalities in patients with ischaemic cerebrovascular disease (ICD) before 55 years of age. Acta Neurol Scand (Suppl 67) 57:251, 1978
Nyman D, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. Platelet-dysfunction and fibrinolytic insufficiency - potential risk factors in ischaemic cerebrovascular disease (ICD)? Acta Neurol Scand (Suppl 67) 57:252, 1978
Soderstrom CE, Mettinger KL, Ericson K, Olivecrona H. A further evaluation of computed tomography (CT) in the diagnosis of cerebrovascular disease. Acta Neurol Scand (Suppl 67) 57:229, 1978
Sjostrom L, Gudmundsson G, Kjellin KG, Mettinger KL, Siden A, Soderstrom CE. Experiences from the stroke unit, Karolinska Hospital. Acta Neurol Scand (Suppl 67) 57:249, 1978
Mettinger KL, Edelund LG, Kjellin KG, Rossner S, Siden A, Soderstrom CE. Lipoproteiner, intravenos glukosbelastning, arbets-EKG - en jamforande studie vid stroke fore 55 ars alder. Riksstamman, 1978
Gudmundsson G, Kjellin KG, Mettinger KL, Siden A, Sjostrom L, Soderstrom CE. Abnormal CSF-protein findings in ischaemic cerebrovascular diseases. International symposium (WHO): Cerebrovascular Disorders and Stroke, Florence, 1978
Mettinger KL, Ericson K, Larsson S, Casseborn S. Detection of atherosclerotic lesions in the carotid arteries using 1231-fibrinogen. International symposium (A7-O): Cerebrovascular Disorders and Stroke, Florence, 1978
Soderstrom CE, Gudmundsson G, Kjellin KG, Mettinger KL, Siden A, Sjostrom L. Experiences from the stroke unit, Karolinska Hospital. International symposium (WHO): Cerebrovascular Disorders and Stroke, Florence, 1978
Soderstrom CE, Mettinger KL, Ericson K, Olivecrona H. A further evaluation of computed tomography (CT) in the diagnosis of cerebrovascular disease. International symposium (WHO): Cerebrovascular Disorders and Stroke, Florence, 1978
Mettinger, KL, Soderstrom CE, Neiman J. and Stroke before 55. A study of 309 patients. International symposium (WHO): Cerebrovascular Disorders and Stroke, Florence, 1978.
Nyman D, Kjellin KG, Mettinger KL, Soderstrom CE. Platelet dysfunction fibrinolytic insufficiency - potential risk factors in ischemic cerebrovascular disease (ICD)? International symposium (WHO): Cerebrovascular Disorders and Stroke, Florence, 1978
Soderstrom CE, Mettinger KL, Blomme C. Verksamheten vid en neurologisk strokeavdelning. Riksstamman, 1979
Mettinger KL, Egberg N. Coagulation studies in 120 patients with verified ischemic cerebrovascular disease (ICD) before the age of 55. World Congress of Angiology, Athens, 1980
Mettinger KL, Soderstrom CE, Allander E. The epidemiology of cerebrovascular disease. The Stockholm study of stroke before 55. World Federation of Neurology: International Symposium of Hemiplegia, Stockholm, 1980
Wahlberg T, Egberg N, Blomback M, Mettinger KL, Wiechel B. Twenty blood coagulation variables in a reference material of 80 blood donors. J Clin Chem Clin Biochem 18:744, 1980
Gudmundsson G, Kjellin KG, Mettinger KL, Siden A, Sjostrom L, Soderstrom CE. Abnormal CSF-protein findings in ischaemic cerebrovascular diseases (ICD). 23rd Scand Neurol Congress, Reykjavik, 1980
Siden A, Kjellin KG, Mettinger KL, Soderstrom CE. HLA-antigens in ischaemic cerebrovascular disease. 23rd Scand Neurol Congress, Reykjavik, 1980
Soderstrom CE, Mettinger KL, Lindstrom P, Sjostrom LO, Sporrstedt L. 5 ars erfarenheter av ett diagnostiskt vardprogram vid en neurologisk stroke-avdelning. Riksstamman, 1981. Hygiea 90(5):345, 1981
Soderstrom CE, Mettinger KL, Lindstrom P. Stroke incidence in the Stockholm community 1970-1979. 24th Scand Neurol Congress, Copenhagen, 1982.
Mettinger KL. Cerebral thromboembolism. A case-control and longitudinal study of blood coagulation, fibrinolysis and platelet function in ischemic cerebrovascular disease. Academic thesis (abstract), Karolinska Institute, Stockholm, 1982
Mettinger KL. Cerebrovascular complications in thrombolysis (abstract). Coronary thrombolysis. International Workshop, Paris, January 1987.
Mettinger KL. Coronary thrombolytic efficacy vs bleeding complications. Results with streptokinase (abstract). 6th European and American cardiology course, Hammersmith, London, June 6-10, 1988. "New aspects of cardiovascular research," 1988
Mettinger KL. Fresh-clot selectivity - a key factor for increased safety? (Abstract) International Satellite symposium, The 9th International Congress on Fibrinolysis, Amsterdam, 1988
Mettinger KL. Controversies in Coronary Thrombolysis. Opening symposium. "World Congress of Cardiology," New Delhi, December 17-20, 1989
Mettinger KL: Clinical use of thrombolytic agents. 25th Anniversary of Indian Surgeons, New Delhi 1988
Mettinger KL What is the Opportunity for New Generations of Thrombolytic Agents? Biomedical Business Symposium, Nice, France, September 1989
Mettinger KL Clinical Use of Thrombolytic Agents. International symposium: "Biotechnology
Applied to Medicine." Consejo Superior de Investigationes Cientificas, Madrid, October 1989
Mettinger KL Controversies in Coronary Thrombolysis. Opening symposium. "World Congress of Cardiology," New Delhi, December 17-20, 1989
Mettinger KL Modulation of learning, pain thresholds and thermoregulation with mixtures of essential fatty acids. Scientific symposium on Alzheimer research organized by University of Miami, 1993
Mettinger KL The decade of brain ischemia: On the threshold of salvage therapy. An update from pharmaceutical research frontiers. 31st Scandinavian Congress of Neurology, Linkoping, Sweden 1996
Gore ME, Vermorken JB, ten Bokkel Huinink W, Trudeau M, Mettinger KL, East D, Jenkins KE, Smalley RV. An international multicenter study of a 3-hour infusion of PaxeneTM (paclitaxel) in platinum-refractory ovarian cancer patients with a rescue to 96-hour infusion on failure. Abstract No. 1251, Program Proceedings, American Society of Clinical Oncology, 33rd Annual Meeting, May 1997
Mettinger KL, Kkarukin M Effects of 4:1 balanced n-6/n-3 supplement and tacrine on water maze reference memory and working memory in medial septal-lesioned rats. First International Conference on The Essential Fatty Acid Balance, University of Miami, October 10-11, 1999
Jacobs D, Burris HA, Rivkin S, Ritch PS, Eisenberg PD, Mettinger KL A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings. Vol 22, No 14S (July 15 Supplement), 4013, 2004
Saba H, Rosenfeld C, Issa J-P, DiPersio J, Raza A, Klimek V, Slack J, de Castro C, Mettinger KL, Kantarjian H: First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS). Session Type: Oral Session Abstract 67 American Society of Hematology Annual Meeting 2004
Harris D, Vidal L, Melcher A, Newbold K, Karavisilis C, Agarwal R, Coffey M, Mettinger K, Kirkpatrick M, Lee J, Twigger KR, White CL, Pandha HS, Debono JS, Harrington KJ. A phase 1 study to evaluate the feasibility, safety and biological effects of intratumoral administration of wild-type reovirus (Reolysin) in combination with radiation in patients with advanced malignancies. Poster AACR 2008
Soefje SA, Sarantopoulos J, Sankhala KK, Mita ACm Mahani JJ, Carmona T, Coffey M, Gill GM, Mettinger K, Mita MM,.A phase II study of intravenous REOLYSIN (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. Abstr # 10568, ASCO 2008
Mita M, Sankhala K, Mita A, Sarantopoulos J, Carmona A, Goel S, Chugh R, Okuno S, Coffey M, Gill G, Mettinger K. A phase II study of intravenous REOLYSIN (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. Chemotherapy Foundation Symposium on Innovative Cancer Therapy for Tomorrow, November 4-7 at the Marriott in NYC, 2008
Karapanagiotou E, Mettinger K et al. Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers With Emphasis on Squamous Cell Carcinoma of the Head and Neck (SCCHN). Poster presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, 2009. Boston. J Clin Oncol. 2009;27(abstr e14519).
Lolkema MP, Harrington K, Evans TRJ, Roxburgh P, Morrison R, Roulstone V, Coffey M, Mettinger K, and de Bono J, A phase-I study of the combination of intravenous reovirus (REOLYSIN) and gemcitabine in patients with advanced cancer. ASCO 2009
Mita A, Mettinger K et al. A phase II study of intravenous (IV) Reolysin (wild type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung Poster presented at the 15th Annual Connective Tissue Oncology Society Meeting, November, 2009, Miami, FL.
Karapanagiotou EM, Chester JD, Pandha HS, Gill GM, Coffey MC, Mettinger K, Harrington KJ, A Phase I/II Study of oncolytic reovirus plus carboplati/paclitaxwl in patients with advanced solid cancers with emphasis on sqquamous cell carcinoma of the head and neck (SCCHN), J CLin nOncol 28: 15s, 2010 (Suppl; ASCO 2010, Abstr 3080)
SCIENTIFIC STUDY REPORTS
Mettinger KL, Soderstrom CE. Hjarninfarkt och hjarnblodning - visst finns det hopp! Utgiven av Stroke Riksforbundet mot hjarnans karlsjukdomar, 1985 (11 pages)
Mettinger KL, Mikaelsson M. AHF-concentrate, 300 IU, heat treated. In vivo study,. KabiVitrum Technical Report 85 98 130, 1985 (6 pages)
Mettinger KL, Mikaelsson M. Octonativ 500 IU, heat-treated, glycine-stabilized. In vivo study. KabiVitrum Technical Report 859 259, 1985 (5 pages)
Mettinger KL. Review of companies involved in tPA development, KabiVitrum Confidential Report, 1985 (8 pages)
Mettinger KL, Erhardt L. Thrombolysis of coronary thrombosis. Recent advances in the treatment of acute myocardial infarction. KabiVitrum, Stockholm, 1986 (15 pages)
Skelding J, Mettinger KL, Leonardi R. Intravenous and intracoronary streptokinase in acute myocardial infarction. A historical review. I. Selected aspects of safety and efficacy. Scientific report 86 96 105, 1986 (58 pages)
Skelding J, Mettinger KL. Intravenous and intracoronary streptokinase in acute myocardial infarction. A historical review. II. Evidence for myocardial salvage. KabiVitrum
Mettinger KL, Skelding J, Leonardi R. High-dose brief-duration intravenous streptokinase in acute myocardial infarction. A review of recent multicenter trials with particular reference to recanalization rate, myocardial salvage, mortality reduction and safety aspects. KabiVitrum Scientific report 86 96 123, 1986 (27 pages)
Mettinger KL. Streptokinase in acute myocardial infarction. Expert opinion. KabiVitrum Scientific report 86 96 107, 1986 (36 pages).
Mettinger KL. Critical questions in thrombolysis answered by Genentech and KabiVitrum. KabiVitrum Confidential Report, 1987 (5 pages).
Mettinger KL. Cerebrovascular complications in thrombolysis. KabiVitrum Scientific report 87 96 070, 1987 (6 pages)
Mettinger KL. Streptokinase in acute myocardial infarction. Expert report submitted on behalf of KabiVitrum and Hoechst to the Food and Drug Administration (FDA), USA, 1987 (42 pages)
Mettinger KL. Report from FDA Advisory Committee Meeting on thrombolytic therapy in AMI, May 29, 1987. KabiVitrum Confidential Report, 1987 (5 pages)
Mettinger KL. The thrombolysis race - a challenge to conventional medical ethics. KabiVitrum Confidential Report, 1988 (13 pages)
Mettinger KL. Adverse reactions of streptokinase therapy. KabiVitrum Expert report 88 96 111, 1988 (24 pages)
The Kabi Manual of Coronary Thrombolysis Trials, 1989 (60 pages)
Mettinger KL. Thrombolytic Therapy: What is the Opportunity for New Generations of Agents?
Proceedings from Biomedical Business Symposium, Nice, France, 1989 (4 pages).
Mettinger KL. Quazepam - A Monograph. Baker Norton Pharmaceuticals, Inc., Miami, 1990 (60 pages)
Mettinger KL, Karukin M. Investigator's Brochure and Related Documents for ALZENE, Confidential Reports, Baker Norton Pharmaceuticals, Inc., 1991 (23 pages)
Yehuda S, Mettinger KL, Karukin M. Cognitive, behavioral and physiological effects of alphalinolenic and linoleic acid mixtures in the rat. Department of Psychology, Bar-Ilan University, Ramat Gan, Israel, 1991.
Yehuda S, Mettinger KL, Karukin M. A dose ranging study of SR-3 (ALZENE) in the rat. Psychopharmacology Laboratory, Bar-Ilan University, Ramat Gan, Israel, 1991
Yehuda S, Mettinger KL, Karukin M. The effects of SR-3 (ALZENE) on selected constituents of brain plasma membrane in the rat. Psychopharmacology Laboratory, Department of Psychology, Bar-Ilan University, Ramat Gan, Israel, 1991
Yehuda S, Mettinger KL, Karukin M. Differential penetration of SR-3 (ALZENE) and its fatty acid components through the blood brain barrier in the rat. Psychopharmacology Laboratory, Department of Psychology, Bar-Ilan University, Ramat Gan, Israel, 1991
Yehuda S, Mettinger KL, Karukin M. A study of acute toxicity of SR-3 (ALZENE) in the rat. Psychopharmacology Laboratory, Bar-Ilan University, Ramat Gan, Israel, 1991
Yehuda S, Mettinger KL, Karukin M. A study of chronic toxicity of SR-3 (ALZENE) in twostrains of rats. Psychopharmacology Laboratory, Bar-Ilan University, Ramat Gan, Israel, 1991
Yehuda S, Carasso RL, Mettinger KL, Karukin M. A double-blind, randomized, placebo controlled study of SR-3 (ALZENE) in one-hundred patients with Alzheimer's disease. Psychopharmacology Laboratory, Bar-Ilan University, Ramat Gan, Israel; Department of Neurology, Hillel Jaffe Hospital, Hadera, Israel, 1991
Yehuda S, Carasso RL, Mettinger KL, Karukin M. A randomized, placebo controlled study of SR-3 (ALZENE) liquid versus SR-3 (ALZENE) capsules in forty-one patients with Alzheimer's disease. Psychopharmacology Laboratory, Bar-Ilan University, Ramat Gan, Israel; Department of Neurology, Hillel Jaffe Hospital, Hadera, Israel, 1991
Sredni B, Albeck M, Mettinger KL, Chen DS, Atkinson DL. Preclinical Pharmacology of IVXQ101 (Ossirene, AS101). Baker-Norton Confidential Report, March 1, 1993 (88 pages)
Mettinger KL, Smith D. Background on Toxicity of Tellurium. Baker Norton Confidential Report, March 1, 1993 (9 pages)
Mettinger KL, Smith D, Atkinson DL. Previous Human Experience of Ossirene (IVX-Q-101 or AS-101). Baker-Norton Confidential Report, March 1, 1993 (39 pages)
Mettinger KL, Smith D. Investigators Brochure: Ossirene, (IVX-Q-101) for protection against chemotherapy induced toxicity. Baker Norton Confidential Report, March 1, 1993 (25 pages)
Mettinger, K.L. OTC development of Alzene and other proprietary essential fatty acid preparations. Scientific rationale. Baker Norton Confidential Report, 1995 (12 pages)
Mettinger KL, East D. Paclitaxel - Investigators Brochure. Baker Norton Confidential Report, January 1995 (23 pages)
Mettinger KL. Cervene - Investigators Brochure, Baker Norton Confidential Report, May 1995 (38 pages)
Mettinger K.L., Chen D. Previous human experience with paclitaxel in published literature.. Baker Norton Confidential Report, 1997 (111 pages)
Mettinger, K.L., Karukin M, New Drug Development of Alzene. Project Summary. Baker Norton Confidential Report, 1998 (22 pages)
Mettinger K.L. Acute Ischemic Stroke. Drugs in Development. Overview. Baker Norton Confidential Report. 1998 (16 pages)
Mettinger KL, Mantelle L, Viti S. A multicenter study of Paxene (Paclitaxel) in advanced Kaposi's Sarcoma (ADS-KS) including liposomal anthracycline failures. Clinical study report, September, 1998 (71 pages)
Mettinger K.L. Alzene - A propriety mixture of essential fatty acids with optimal omega3/omega-6 ratio. Scientific Report, IVAX Nutraceuticals, March 1999 (9 pages)
Mettinger K.L. Treatments for Parkinson's Disease. Drugs in development. July 1999, (20 pages)
Mettinger K.L. Angiogenesis inhibitors and other tumoristatic agents in clinical development, August 1999 (15 pages)
Mettinger K.L. , Mantelle L., Viti S, Marcus S An international randomized Phase III study of paclitaxel in metastatic breast cancer (Clinical study report, 75 pages), 1999
Mettinger K.L., Mantelle L, Viti S, Marcus S. Phase III trial of 3-hour infusion of Paxene (Paclitaxel) in patients with refractory ovarian cancer, with rescue to a 96-hour infusion on failure of 3-hour infusion. (Clinical Study Report, 50 pages), 1999
Mettinger K.L., Duchin K.L. PAXORAL (Oral Paclitaxel) Investigator's Brochure (76 pages), April 2000
Mettinger K.L. Duchin K.L. ONXOLTM (Paclitaxel Injection). Clinical Monograph (12 pages), June 2000
Mettinger K.L. Clinical Study Report. Study of the tolerance and efficacy of Mitoextra in patients with solid tumors who have failed previous therapy, SuperGen, 2002 (91 pages)
Mettinger K.L. Clinical Study Report. Phase 3 study of RFS 2000 (9-NITRO-CAMPTOTHECIN) Capsules vs. most appropriate therapy in refractory pancreatic cancer patients (RFS 2000-09), 2004
Mettinger K.L. Clinical Study Report. Phase 3 randomized study of Orathecin (rubitecan) Capsules vs. 5-fluorouracil (5-FU) in pancreatic cancer patients that have progressive disease following gemcitabine-HCL treatment. ^RFS 2000-06), 2004
Mettinger K.L. Clinical Study Report. An open-label multi-center, Phase 2 study of Orathecin (oral rubitecan 9-NITRO-CAMPTOTHECIN, 9-NC) in pancreatic cancer patients who have failed previous chemotherapy (RFS 2000-02), 2003
Mettinger K.L. Clinical Study Report. Rescue phase of RFS-2000-09 multi-center study, 2004
Mettinger K.L. Clinical Study Report. Rescue phase of RFS 2000-06 mult-icenter study, 2004
Mettinger K.L. Clinical Study Report. Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin; 9-NC) Administered as a 5 Days On – 2 Days Off” Oral Treatment in Patients with Glioblastoma Multiforme — EORTC Study 16996G (RFS 2000-05G), 2004
Mettinger K.L. Clinical Study Report. A Phase 1 and pharmacokinetic study of RFS 2000 (9-NITRO-20-(S)-CAMPTOTHECIN, 9-NC) in patients with solid malignancies (RFS 2000-08), 2003
Mettinger K.L. Clinical Study Report. Phase 2 evaluation of rubitecan (RFS 2000; 9-NITRO-CAMPTOTHECIN) in metastatic melanoma (RFS 2000-10), 2004
Mettinger K.L. Clinical Study Report. Phase 2 trial with RFS 2000 (Orathecin™) in patients with colorectal cancer (RFS 2000-12CR), 2004
Mettinger K.L. Clinical Study Report. Phase ! study of Orathecin (RUBITECAN) and gemcitabine in the treatment of patients with refractory malignancies (RFS 2000-13), 2004
Mettinger K.L. Clinical Study Report. Open-label P{hase 2 study of OrathecinÔ (RUBITECAN) Capsules in relapsed non-small cell lung cancer (NSCLC) (RFS 2000-16), 2004
Mettinger K.L. Clinical Study Report. Open- label Phase 2 study of OrathecinÔ (rubitecan)
Mettinger K.L. Clinical Study Report. Capsules in patients with relapsed metastatic breast cancer (RFS 2000-17), 2004 (RFS 2000-17), 2004
Mettinger K.L. Clinical Study Report. Phase 2 and pharmacokinetic study of RFS 2000 (9‑NITRO‑CAMPTOTHECIN, 9‑NC) in patients with advanced colorectal cancer who have failed previous 5-FU based chemotherapy (RFS 2000-18), 2004
Mettinger K.L. Clinical Study Report. Phase 2 study of Orathecin (RUBITECAN, RFS 2000) in patients with sofr-tissue sarcoma (RFS 2000-24), 2004
Mettinger K.L. Clinical Study Report. Open-label Phase 2 study of Orathecin (RUBITECAN) Capsules in patients with recurrent metastatic breast cancer (RFS 2000-33), 2004
Mettinger K.L. Clinical Study Report. A pharmacokinetic and bioequivalence study of two formulations (A or C) of orathecin™ (Rubitecan) capsules in patients with solid malignancies (RFS 2000-33), 2004
Mettinger K.L. Clinical Study Report. Phase III Randomized Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) versus gemcitabine HCl in chemonaive pancreatic cancer patients (RFS 2000-02), 2004
Mettinger K.L. Clinical Study Report. Phase II study of RFS 2000 (9-nitro-camptothecin, 9-NC) in Unresectable Chordoma Patients (previously titled in Incurable Sarcoma Patient)Phase II (RFS 2000-04), 2004
Mettinger K.L. Clinical Study Report. Phase II Study of Oral 9-Nitro-20- (S) – Camptothecin (9-NC) in Myelodysplastic Syndrome (MDS), Chronic Myeloid Leukemia (CML) and other Myelo-proliferative Disorders (MPD) (RFS 2000-07), 2004
Mettinger K.L. Clinical Study Report. A Phase I Trial Of 9-Nitro Camptothecin (9-NC) (RFS2000) given concurrently with Capecitabine in patients wth metastatic solid tumors (RFS 2000-25), 2004
Mettinger K.L. Clinical Study Report. Phase I Study of combination therapy with oral 9-Nitrocamptothecin and oral Etoposide (RFS 2000-29), 2004
Mettinger K.L. Clinical Study Report. Phase I and pharmacokinetic study of 9 -Nitrocamptothecin, (9-NC, RFS2000) in advanced malignancies (RFS 2000-37), 2004
Mettinger K.L. Clinical Study Report. Randomized, open-label Phase 3 trial of decitabine (5‑Aza‑2'‑deoxycitadine) vs. supportive care in adults with advanced-stage myelodysplastic syndrome ( HYPERLINK "X:\\DAC CSR\\Phase 3 Decitabine 0007 CSR v8.doc" D-0007), 2004
Mettinger K.L. Clinical Study Report. A Phase 2 multi-center trial of decitabine (5‑Aza‑2'‑deoxycitadine) in patients with myelodysplastic syndromes (MDS) ( HYPERLINK "X:\\95-11" PCH 95-11), 2004
Mettinger K.L. Clinical Study Report. Compassionate use of decitabine (5‑Aza‑2'‑deoxycitadine) in patients with myelodysplastic syndromes (MDS) (PCH 97-19), 2004
Mettinger K.L. Clinical Study Report. Phase 1-2 pilot study of (5‑Aza‑2'‑deoxycitadine in patients with acute myeloid leukemia and myelodysplastic syndrome (PCH 88-01), 2004
Mettinger K.L. Clinical Study Report. A Phase 2 trial of 5‑Aza‑2'‑deoxycitadine (DECITABINE, DAC) single agent in patients with myelodysplastic syndromes (HYPERLINK "91-01"PCH 91-01), 2004
Mettinger K.L. Clinical Study Report. A Phase 2 trial of 5‑Aza‑2'‑deoxycitadine (DECITABINE, DAC) as a continuous infusion in patients with myelodysplastic syndromes (PCH 91-02), 2004
Mettinger K.L. Clinical Study Report. Phase 2 study of A Phase 2 trial of 5‑Aza‑2'‑deoxycitadine (DECITABINE, DAC) single agent in patients with myelodysplastic syndromes (PCH 95-04), 2004
Mettinger K.L. Clinical Study Report. Differentiation therapy with 5‑Aza‑2'‑deoxycitadine for myelodysplastic syndromes (PCH 95-05), 2004
Mettinger K.L. Clinical Study Report. Clinical trial of 5-Aza-2’-deoxycytadine in patients with acute leukemia (PCH 79-01), 2004
Mettinger K.L. Clinical Study Report. Phase I study of intravenous infusion of 5-Aza-2’-deoxycytadine in children with acute leukemia resistant to conventional therapy (PCH 79-02), 2004
Kulmala H, Kirkpatrick M, Coffey M, Mettinger K.L., Gill G A Phase 1 clinical trial to evaluate dose-limiting toxicity and maximum tolerated dose of intralesion al administration of REOLYSIN for the treatment of histologically confirmed malignancies. Oncolytics CSR 2007
Kulmala H, Kirkpatrick M, Coffey M, Mettinger K.L. , Gill G An evaluation of Intraprostate administration of REOLYSIN for the treatment of T2 prostate cancer prior to definitive surgery. Oncolytics CSR 2007
Kulmala H, Kirkpatrick M, Coffey M, Mettinger K.L. , Gill G A Phase I/II Clinical Trial to Evaluate DoseLimiting Toxicity and Efficacy of Intralesional Administration of REOLYSINÒ for the Treatment of Patients with Histologically Confirmed Recurrent Malignant Gliomas. Oncolytics CSR 2007
Kulmala H, Kirkpatrick M, Coffey M, Mettinger K.L. , Gill G A A Phase I Study to Evaluate the Feasibility, Safety, and Biological Effects of Administering a Wild-Type Reovirus (REOLYSIN®) that Selectively Replicates in Cells Expressing Activated Ras, Intravenously to Patients with Advanced Malignancies. Oncolytics CSR 2008
Kulmala H, Kirkpatrick M, Coffey M, Mettinger K.L. , Gill G, A Phase I Study to Evaluate the Feasibility, Safety, and Biological Effects of Intratumoral Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Radiation in Patients with Advanced Malignancies. Oncolytics CSR 2008
Dahl N, Kirkpatrick M, Mettinger K.L., Gill G A A Multicenter Single-Arm Phase I Study to Evaluate the Biological Effects of Intratumoral Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Low-Dose Radiation in Patients with Advanced Cancers. Oncolytics CSR 2010
Dahl N, Kirkpatrick M, Mettinger K.L. , Gill G A A Phase I Study to Evaluate the Feasibility, Safety, and Biological Effects of Intravenous Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Gemcitabine in Patients with Advanced Malignancies. Oncolytics CSR 2010
Dahl N, Kirkpatrick M, Mettinger K.L. , Gill G A A Phase I Study to Evaluate the Feasibility, Safety, and Biological Effects of Intravenous Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Docetaxel in Patients with Advanced Malignancies. Oncolytics CSR 2010
Dahl N, Kirkpatrick M, Mettinger K.L. , Gill G A A Phase I Study to Evaluate the Feasibility, Safety, and Biological Effects of Intravenous Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Carboplatin/Paclitaxel in Patients with Advanced Malignancies. Oncolytics CSR 2011
ORAL PRESENTATIONS
Medical therapy in ischemic cerebrovascular diseases with special regard to the bioavailability of coumarine derivatives. VII Neurological Congress with International Participation, Bratislava 1976
Transitoric Ischemic Attacks before Age 55. Annual Meeting of Swedish Medical Society, 1976
Circulating platelet aggregates, fibrinolytic response and factor VIII related antigen (VIII RA) in ischemic cerebro-vascular disease (ICD). A study of stroke before 55. 11th World Congress of Neurology, Amsterdam, 1977 Fibromuscular dysplasia (FMD). A neglected risk factor for stroke before 55? 11th World Congress of Neurology, Amsterdam, 1977
A model for non-invasive screening of ulcerous plaques in the carotid arteries using isotope labeled blood elements. 11th World Congress of Neurology, Amsterdam, 1977
Stroke in females before 55. A study of 103 patients. 11th World Congress of Neurology, Amsterdam, 1977
Coumarin derivatives in ischemic cerebro-vascular disease (ICD). A pharmacological comparison. 11th World Congress of Neurology, Amsterdam, 1977
Development of a neurologic stroke unit. Symposium organized by Swedish Medical Society and The Swedish Government Planning and Rationalization Institute, 1978
Detection of atherosclerotic lesions in the carotid arteries using 123I-fibrinogen. International Symposium (WHO): Cerebrovascular Disorders and Stroke, Florence, 1978
A study of 309 young stroke patients. International symposium (World Health Organization): Cerebrovascular Disorders and Stroke, Florence, 1978
Platelet dysfunction fibrinolytic insufficiency - potential risk factors in ischemic cerebrovascular disease (ICD)? International symposium (WHO): Cerebrovascular Disorders and Stroke, Florence, 1978 Lipoproteiner, intravenos glukosbelastning, arbets-EKG - en jamforande studie vid stroke fore 55 ars alder. Annual Meeting of Swedish Medical Society, 1978
Coagulation studies in 120 patients with verified ischemic cerebrovascular disease (ICD) before the age of 55. World Congress of Angiology, Athens, 1980
The epidemiology of cerebrovascular disease. The Stockholm study of stroke before 55. World Federation of Neurology: International Symposium of Hemiplegia, Stockholm, 1980
Antitrombotisk behandling efter cerebral infarkt. National Board of Health and Welfare, Drug Information Committee, Sweden. Workshop Cerebrovaskular Ischemi 1980
Medicine or patients? Proceedings of the Seventh International Congress of Christian Physicians. Christian challenge to current concepts of health care, pp 40-44. Ashok Hotel, Bangalore, India, November 3-7, 1982
A study of hemostasis in ischemic cerebrovascular disease. International Conference – Rome, 30-31October 1983
Responsibility and accountability. Lecture. First European Congress of Christian Physicians, Strasbourg, 1984
Cerebrovascular complications in thrombolysis. Coronary thrombolysis. International Workshop, Paris, January 1987
Thrombolytic agents. Seminar in London for investors, organized by Greenwell Montegu Investment bank, 1988
Coronary thrombolytic efficacy vs bleeding complications. Results with streptokinase. 6th European and American cardiology course, Hammersmith, London, June 6-10,1988. "New aspects of cardiovascular research," 1988
Fresh-clot selectivity - a key factor for increased safety? International Satellite symposium, The 9th international congress on fibrinolysis, Amsterdam, 1988
Clinical use of thrombolytic agents. 25th Anniversary of Indian Surgeons, New Delhi 1988
What is the Opportunity for New Generations of Agents? Biomedical Business Symposium, Nice, France, September 1989
Clinical Use of Thrombolytic Agents International symposium: "Biotechnology Applied to Medicine." Consejo Superior de Investigationes Cientificas, Madrid, October 1989
Controversies in Coronary Thrombolysis. Opening symposium. "World Congress of Cardiology," New Delhi, December 17-20,1989.
Recent developments in receptor selective hypnotics. Grand Rounds, Univeriity of Florida, Gainesville, University of Miami, Albert Einstein, 1990
Modulation of learning, pain thresholds and thermoregulation with mixtures of essential fatty acids. Scientific symposium on Alzheimer research organized by University of Miami, 1993
Alternative Practices of Medicine. University of Miami Student Council Convention, 1996
The decade of brain ischemia: On the threshold of salvage therapy. An update from pharmaceutical research frontiers. 31st Scandinavian Congress of Neurology, Linkoping, Sweden 1996
Effects of 4:1 balanced n-6/n-3 supplement and tacrine on water maze reference memory and working memory in medial septal-lesioned rats. First International Conference on The Essential Fatty Acid Balance, University of Miami, October 10-11, 1999
“Heart Attacks and Clot Buster Wars: A Chapter in the History of Modern Biotech. Insights and Reflections” Presentation to the Bay Area History of Medicine Club, UCSF, January 2003
"TRIALS AND TRIUMPHS -THE 30 YEAR BIOTECH WARS: A Chapter in the History of Modern Medicine. Insights and Reflections" Presentation to the Bay Area History of Medicine Club, UCSF, May 2006
Reovirus –An oncolytic virus to treat RAS activated cancers. Oral presentation at the Sixth International Congress on Targeted Therapies in Cancer. Renaissance Mayflower Hotel
Washington, DC, August 24-26, 2007
Numerous presentations to financial analysts at investment conferences in the US and Europe